Gilead Sciences (NASDAQ:GILD) Posts Earnings Results, Beats Expectations By $0.36 EPS

Gilead Sciences (NASDAQ:GILD) announced its earnings results on Thursday. The biopharmaceutical company reported $2.55 earnings per share for the quarter, topping the consensus estimate of $2.19 by $0.36, FiscalAI reports. The business had revenue of $8.30 billion during the quarter, compared to the consensus estimate of $7.80 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%. The business’s quarterly revenue was up 6.8% on a year-over-year basis. During the same period in the prior year, the company posted $2.47 EPS.

Here are the key takeaways from Gilead Sciences’ conference call:

• Strong third-quarter execution: Base business sales rose 16% year over year to $8.2 billion, led by HIV products, TRODELVY, and Livdelzi. Gilead raised its 2026 base-business revenue guidance by $900 million at the midpoint.
• HIV momentum remained robust, with sales up 18% and BIKTARVY reaching a record 53% U.S. treatment share. Yeztugo sales reached $305 million for the quarter and are tracking toward approximately $1 billion for the full year, while the Bixlenvo launch is reportedly progressing ahead of comparable launches.
• The company highlighted a broadening growth pipeline, including a potential 2027 filing for once-weekly oral HIV treatment, additional long-acting HIV options, seven clinical-stage oncology ADC programs, and 13 inflammation programs. Management also expects a potential anito-cel approval in December for relapsed or refractory multiple myeloma.
• CMS set BIKTARVY’s Medicare price at $2,600 per 30-day supply, approximately 38% below list price. Gilead preliminarily estimates a roughly $1.5 billion net revenue impact in 2028, including spillover effects across Medicaid, 340B, and other U.S. channels.
• Cell therapy sales declined 18% year over year because of competitive pressure, and the PALISADES-1 and -2 studies of KITE-753 are on partial clinical hold while the company investigates higher-grade ICANS differences between trial phases. Gilead said there were no patient deaths but paused the studies pending further review.

Gilead Sciences Stock Up 4.0%

GILD stock traded up $6.41 during midday trading on Thursday, reaching $165.61. The stock had a trading volume of 8,397,874 shares, compared to its average volume of 5,751,038. The company’s fifty day simple moving average is $150.33 and its 200 day simple moving average is $139.55. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03. Gilead Sciences has a 52-week low of $114.02 and a 52-week high of $165.70.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead reported non-GAAP earnings of $2.55 per share, beating analysts’ $2.19 estimate by $0.36. Quarterly revenue reached $8.30 billion, exceeding expectations by approximately $500 million. Gilead Sciences Non-GAAP EPS and Revenue Beat
• Positive Sentiment: The company raised its full-year product-sales forecast to $31.0 billion-$31.3 billion, up from $30.1 billion-$30.4 billion, citing continued momentum across its HIV portfolio. Biktarvy remains the primary growth driver. Gilead Sciences Lifts Sales Guidance on HIV Portfolio Strength
• Positive Sentiment: Gilead completed negotiations for Canadian reimbursement of Lyvdelzi, its liver-disease treatment. Broader reimbursement access could support the drug’s commercial rollout and provide an additional growth opportunity. Gilead Reaches Canadian Reimbursement Deal for Lyvdelzi
• Neutral Sentiment: Robert W. Baird maintained a Hold rating, suggesting the earnings strength is balanced by questions about growth outside the HIV franchise. Gilead Sciences Gets a Hold from Robert W. Baird
• Negative Sentiment: Analyst commentary indicates that Gilead’s non-HIV businesses remain a work in progress, while some coverage has highlighted continued cash usage. These issues could limit valuation expansion if the company cannot diversify growth beyond Biktarvy and its broader HIV portfolio. Gilead’s HIV Franchise Powers Earnings Beat

Analyst Ratings Changes

A number of research firms recently issued reports on GILD. Needham & Company LLC reissued a “buy” rating and issued a $170.00 price target on shares of Gilead Sciences in a research note on Wednesday, August 5th. Leerink Partners downgraded shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and reduced their price target for the stock from $146.00 to $127.00 in a research report on Tuesday, July 21st. Cantor Fitzgerald restated an “overweight” rating and set a $155.00 price target on shares of Gilead Sciences in a research report on Thursday, October 8th. Zacks Research lowered shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 29th. Finally, HSBC lifted their price objective on Gilead Sciences from $155.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, September 10th. Twenty-three research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $159.81.

Insider Activity at Gilead Sciences

In other news, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $156.22, for a total transaction of $468,660.00. Following the completion of the sale, the insider owned 113,684 shares of the company’s stock, valued at $17,759,714.48. This represents a 2.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew Dickinson sold 3,000 shares of the stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $156.22, for a total transaction of $468,660.00. Following the completion of the sale, the chief financial officer owned 161,096 shares of the company’s stock, valued at $25,166,417.12. This trade represents a 1.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 111,000 shares of company stock worth $15,877,860 over the last 90 days. Corporate insiders own 0.30% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.